Why was Denali able to raise a $217MM Series A? Find out the special ingredients that broke the Series A ceiling.
Denali debuted in 2015 to work in neurodegenerative diseases with a biotech record breaking $217MM Series A investment from top tier venture capitalists. Ryan headed neuroscience at Genentech; the founder group includes Stanford’s new president. With an all-star team and a novel approach to Alzheimer’s and Parkinson’s, the rationale for that level of investment emerges. Ryan will speak about forming the company, how he is putting the funds to work (now including a $130MM Series B) and how he intends to reverse the industry’s long record of failure in Alzheimer's and Parkinson's diseases with an approach that applies the translational rigor seen in oncology. Tickets.